Optimizing carboplatin dosing using Computed Tomography derived body composition and serum creatinine

• Conditions: Lung cancer; ovarian cancer; 10027656

• Registration Number: NL-OMON56726
• Lead Sponsor: Amphia Ziekenhuis

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 6 May 2024

Recruitment & Eligibility

• Status: Pending
• Sex: Not specified
• Target Recruitment: 40

Inclusion Criteria

- Age 18 years or older
- Available contrast-enhanced enhanced CT-scan including L3 at baseline before
carboplatin treatment (at least of six weeks before start of therapy)

Exclusion Criteria

- Conditions that affect hemostasis in a way that blood drawing is complicated
(to be assessed by a physician)
- Drugs that inhibit creatinine clearance in the kidneys, like cimetidine,
trimethoprim, pyrimethamine, and salicylates (>100 mg)
- A carboplatin target AUC of below 4 mg/mL*min

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>The covariate relationship between CT-derived body composition, serum<br /><br>creatinine, and carboplatin pharmacokinetics. </p><br>

Secondary Outcome Measures

Name	Time	Method
<p>o The bias (Mean Percentage Error, MPE%), the imprecision (Mean Absolute<br /><br>Percentage Error, MAPE%) and the accuracy (Root Mean Squared Error, RMSE) of<br /><br>the predicted AUC versus the target AUC<br /><br>o The percentage of patients within 90-110% the target AUC will be assessed </p><br>